| symbol | subject | date & time | rating |
|
|
Paway, It's not because there's no news release that nothing is happening. There's a lot of work in progress. There's a lot of paper work regarding IND's filing, so PBI-4050 can be ready in September, but mior delays aren... |
6/18/2013 7:16:16 AM |
|
|
|
No dammage on this, as PLI wasn't involved in this product. However, this is the kind of product that PLI could give a second life to the patent. And as PLI and Octapharma have a really good business relation, I wouldn't be surprise to ... |
5/1/2013 10:33:15 AM |
|
|
|
Because, this the game PLI is playing. Putting slowly the pieces at the right place. How good is the technology? Well, CNBG seems to have a successfull scale up with PPPS. Sartorius wants his name with it. Hematech, Nantpharma are paying for all ... |
4/30/2013 6:03:47 PM |
4 |
|
|
The NR don't mentionned numbers, but could worth $ 5M, as it was the estimate cost of equipment in Laval: ... |
4/30/2013 6:06:57 AM |
|
|
|
Just notice that Frédéric Dumais bought yesterday 15K shares at 30.5 cents. I guess this means no bad news on the way!!! |
4/20/2013 1:41:10 PM |
4 |
|
|
I don't think there will be either huge surprises or huge deceptions with the financials on thuesday. I don't know what are exactly people's expectations, but the management have already put the cards on the table. I'm pretty... |
3/24/2013 11:10:23 AM |
5 |
|
|
Vinny, I've never said that the revenues for plasminogen could reach $ 1B. Based on conservative estimate of $ 50M a year of sales, I've said that once approuved, this drug could add to the market cap value something like $ 500M to $ ... |
3/20/2013 4:04:02 PM |
4 |
|
|
Mystical, I don't clearly understand your logic. A blockbuster drug is a drug that generate $ 1B in sale. So, what this study is saying, is at least 25 orphan had each $ 1B in sales. My point wasn't to try to figure out what are the... |
3/20/2013 11:49:32 AM |
4 |
|
|
I can't say if it's me or the market just don't understand the real value of this orphan drug. PLi got something here, for which the cost of development is paid by the partner. Maybe it's not viagra, but this kind of drug is cle... |
3/20/2013 9:40:44 AM |
3 |
|
|
Now people can't say they are not working on real stuff. Faster approbation, but a smaller market. However the revenues per dose of an oprhan drug are much higher. |
3/14/2013 7:22:27 AM |
3 |
|
2/4/2009 8:59:41 AM
| 545 reads
| 1 comments
For those who likes technical analysis, when the line cross above -100, it suggest a reversal. Usually, people that short the stock should cover their position.
1/1/2009 3:02:03 PM
| 543 reads
| overall quality: 1
May 2009 be the pivotal year for PLI.We finally have a nice end of year in 2008. All technical signals are positive. Let 2009 start strong and I hope for 30 cents at the end of january.Good luck to all long shareholders!
Stockhouse.com: Taking
it to the street
